SI: Ascending Triangle detected on 13 Mar 2026

Shoulder Innovations recently reported FY 2025 revenue of $47.3 million with a net loss of $4.65 per share, and the pattern forms on an ascending triangle with structure, breakout, and volume scores of 12.5, 13.0, and 12.0 respectively (overall 87.5/98). At $14.62, SI trades within the triangle between support at $12.79 and resistance at $15.12. The high volume ratio of 1.81x average and bullish 74.45% win probability indicate strong participation. Q4 2025 revenue surged 65% to $14.4 million, and the post-collapse recovery pattern spanning 82 days shows the stock is rebuilding from prior weakness.

Fourth quarter net revenue rose 65% to $14.4 million with gross margin of 77%, driven by higher implant system volumes and new customers. However, operating expenses climbed sharply, leading to a 2025 operating loss of $26.3 million, though the company ended 2025 with $124.3 million in cash. BTIG raised its price target to $24 from $23 on Wednesday while maintaining a Buy rating, and Shoulder Innovations set fiscal 2026 revenue guidance of $62-65 million, representing 31-37% year-over-year growth and ahead of the Street's $58.8 million estimate. According to 5 analysts, the average rating for SI stock is "Strong Buy". CEO Robert Joseph Ball purchased 3,900 shares on December 12th at an average cost of $14.89 per share, showing insider confidence. This positive earnings beat coupled with strong guidance and elevated analyst sentiment explain the pattern forming now.

The ascending triangle suggests a potential breakout above $15.12 resistance. The conservative target of $15.36 implies modest upside from current levels—roughly 5% to breakout completion. Volume confirmation is critical; the 1.81x relative volume ratio already demonstrates above-average participation, supporting the notion that breakout volume should exceed the pattern's average. Invalidation occurs if price breaks below key support of $12.79 (2.8% downside), which would negate the bullish setup. With a 74.45% win probability, the pattern has favorable historical odds. Success requires price to move through $15.12 with sustained volume, testing the measured move extension.

Profitability remains elusive—the company posted a net loss of $40.4 million in 2025, and analysts do not anticipate profitability this year. High operating expense growth and public-company costs pressure near-term earnings. Director Michael Carusi notified the company on March 6, 2026 of his intention to not stand for re-election, with his term concluding at the 2026 Annual Meeting—a director departure just announced warrants monitoring for execution risk. RSI at 63.08 is neutral, but ATR at 5.13% combined with beta of 1.0 reflects moderate volatility. The stock trades as a micro-cap focused on niche shoulder implants; concentrated market exposure and limited surgeon adoption history create execution risk. No major sector headwinds evident, but medical device companies face regulatory, competitive, and clinical trial risks.